Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right-sided colon adenocarcinoma

BACKGROUND Changes in bowel function after right-sided colectomy are not well understood compared to those associated with left-sided colectomy or rectal resection.In particular,there are concerns about bowel function after right-sided colectomy with complete mesocolic excision,which has become popular in the West.AIM To evaluate the functional outcomes of patients who underwent right-sided colectomy with D3 lymphadenectomy for colon cancer.METHODS Functional data from patients who underwent minimally invasive right-sided colectomy for colon cancer from October 2017 to September 2018 were prospectively collected.Functional outcomes were evaluated preoperatively and at 3,6,12,and 18 mo postoperatively.RESULTS Prior to surgery,57 patients answered the questionnaire,and 47 responded at three months,52 at 6 mo,52 at 12 mo,and 25 at 18 mo postoperatively.Most scales of quality of life and bowel function improved significantly over time.Urgency persisted to a high degree throughout the period without a significant change over time.The use of medications for defecation was about 10%over the entire period.Gas(P=0.023)and fecal frequency(P<0.001)increased,and bowel dysfunction group(P=0.028)was more common among patients taking medication.At six months,resected bowel and colon lengths were significantly different as a risk factor between the dysfunction group and the no dysfunction group[odd ratio(OR):1.095,P=0.026;OR:1.147,P=0.031,respectively]in univariate analysis,but not in multivariate analysis.CONCLUSION Despite D3 lymphadenectomy,most bowel symptoms improved over time after right-sided colectomy using a minimally invasive approach,and continuous medication was needed in only approximately 10%of patients.

Colonic pouch confers better bowel function and similar postoperative outcomes compared to straight anastomosis for low rectal cancer

BACKGROUND With advancements in laparoscopic technology and the wide application of linear staplers,sphincter-saving procedures are increasingly performed for low rectal cancer.However,sphincter-saving procedures have led to the emergence of a unique clinical disorder termed anterior rectal resection syndrome.Colonic pouch anastomosis improves the quality of life of patients with rectal cancer>7 cm from the anal margin.But whether colonic pouch anastomosis can reduce the incidence of rectal resection syndrome in patients with low rectal cancer is unknown.AIM To compare postoperative and oncological outcomes and bowel function of straight and colonic pouch anal anastomoses after resection of low rectal cancer.METHODS We conducted a retrospective study of 72 patients with low rectal cancer who underwent sphincter-saving procedures with either straight or colonic pouch anastomoses.Functional evaluations were completed preoperatively and at 1,6,and 12 mo postoperatively.We also compared perioperative and oncological outcomes between two groups that had undergone low or ultralow anterior rectal resection.RESULTS There were no significant differences in mean operating time,blood loss,time to first passage of flatus and excrement,and duration of hospital stay between the colonic pouch and straight anastomosis groups.The incidence of anastomotic leakage following colonic pouch construction was lower(11.4%vs 16.2%)but not significantly different than that of straight anastomosis.Patients with colonic pouch construction had lower postoperative low anterior resection syndrome scores than the straight anastomosis group,suggesting better bowel function(preoperative:4.71 vs 3.89,P=0.43;1 mo after surgery:34.2 vs 34.7,P=0.59;6 mo after surgery:22.70 vs 29.0,P<0.05;12 mo after surgery:15.5 vs 19.5,P=0.01).The overall recurrence and metastasis rates were similar(4.3%and 11.4%,respectively).CONCLUSION Colonic pouch anastomosis is a safe and effective procedure for colorectal reconstruction after low and ultralow rectal resections.Moreover,colonic pouch construction may provide better functional outcomes compared to straight anastomosis.

Effects of cereal fiber on bowel function: A systematic review of intervention trials

AIM: To comprehensively review and quantitatively summarize results from intervention studies that examined the effects of intact cereal dietary fiber on parameters of bowel function. METHODS: A systematic literature search was conducted using Pub Med and EMBASE. Supplementary literature searches included screening reference lists from relevant studies and reviews. Eligible outcomes were stool wet and dry weight, percentage water in stools, stool frequency and consistency, and total transit time. Weighted regression analyses generated mean change(± SD) in these measures per g/d of dietary fiber. RESULTS: Sixty-five intervention studies among generally healthy populations were identified. A quantitative examination of the effects of non-wheat sources of intact cereal dietary fibers was not possible due to an insufficient number of studies. Weighted regression analyses demonstrated that each extra g/d of wheat fiber increased total stool weight by 3.7 ± 0.09 g/d(P < 0.0001; 95%CI: 3.50-3.84), dry stool weight by 0.75 ± 0.03 g/d(P < 0.0001; 95%CI: 0.69-0.82), and stool frequency by 0.004 ± 0.002 times/d(P = 0.0346; 95%CI: 0.0003-0.0078). Transittime decreased by 0.78 ± 0.13 h per additional g/d(P < 0.0001; 95%CI: 0.53-1.04) of wheat fiber among those with an initial transit time greater than 48 h.CONCLUSION: Wheat dietary fiber, and predominately wheat bran dietary fiber, improves measures of bowel function.

Efficacy of a Kiwifruit Extract (PhenActivTM) on Gastrointestinal Tract Function: A Randomised Double-Blind Placebo-Controlled Study

Objective: Gastrointestinal (GI) discomfort is experienced by millions of people every day. This study aimed to evaluate the effect of PhenActivTM, a novel green kiwifruit extract, on gastrointestinal tract (GIT) function in otherwise healthy adults. Methods: 41 healthy adults with mild GI discomfort were enrolled in this double-blind, randomized, placebo-controlled study. Participants were randomized to either take 3.0 g/day of PhenActivTM or a placebo for 6 weeks. Interviews were conducted at baseline, week 3 and week 6, with participants completing questionnaires regarding GI symptoms. Frequency of bowel movements was self-recorded daily. Results: There were no differences in daily and weekly defecation frequency and stool characteristics in either group. The active and placebo groups significantly improve GSRS scores (p , only the active group had a significant improvement in the IBSSS and PAC-QOL scores (p < 0.05) from baseline. Neither group had changes in sleep quality, quality of life and fatigue, plasma zonulin concentrations or macular pigment optical density scores. The product was well tolerated with no GI disturbances or adverse events being reported. Conclusion: Supplementation of 3.0 g/day of PhenActivTM for 6 weeks did not improve defecation frequency or stool composition in healthy adults, but did improve perceived symptoms of GIT function, including symptoms of functional GIT disorders, IBS and constipation. The product was well tolerated and future trials investigating higher doses with more participants and/or a different population would be beneficial.

Investigation of the effect of military stress on the prevalence of functional bowel disorders

AIM: To investigate the morbidity of functional bowel disorders (FBD) under military stress conditions in order to lay foundations for the prevention and treatment of this disease. METHODS: Four hundred and fifty-seven soldiers who were assigned to specified services and 471 soldiers who were assigned to routine services were enrolled using cluster sampling, with the latter as a control group. They were surveyed using the Rome Ⅲ FBD standard questionnaire. The FBD symptom question-naire included FBD-related symptoms, severity, dura- tion or attack time, and accompanying symptoms. RESULTS: The morbidity of the military stress group (14.6%) was significantly higher than in the control group (9.98%) ( 2 = 4.585, P < 0.05). The incidence of smoking, abdominal pain and acid regurgitation ( 2 = 4.761, P < 0.05) as well as the ZUNG anxiety/depression scores ( 2 = 7.982, P < 0.01) were also sig- nificantly higher in the military stress group compared with the control group. ZUNG anxiety ( 2 = 11.523, P < 0.01) and depression ( 2 = 5.149, P < 0.05) scores were higher in the FBD group compared with the non-FBD group. The differences in the ZUNG self-rated anxiety and depression scales between the 2 groups were statistically significant ( 2 = 14.482, P < 0.01 and 2 = 6.176, P < 0.05). CONCLUSION: The morbidity of FBD was higher under military stress conditions.

Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review

BACKGROUND Irritable bowel syndrome(IBS)and functional constipation(FC)are two commonly encountered functional gastrointestinal disorders in clinical practice and are usually managed with Western medicines in cooperation with traditional Chinese medicine(TCM)interventions.Although clinical practice guidelines(CPGs)have been developed to assist clinicians with their decisions,there are still gaps in management with regard to integrative medicine(IM)recommendations.AIM To comprehensively review the currently available CPGs and to provide a reference for addressing the gaps in IBS and FC management.METHODS We searched mainstream English and Chinese databases and collected data from January 1990 to January 2019.The search was additionally enriched by manual searches and the use of publicly available resources.Based on the development method,the guidelines were classified into evidence-based(EB)guidelines,consensus-based(CB)guidelines,and consensus-based guidelines with no comprehensive consideration of the EB(CB-EB)guidelines.With regard to the recommendations,the strength of the interventions was uniformly converted to a 4-point grading scale.RESULTS Thirty CPGs met the inclusion criteria and were captured as data extraction sources.Most Western medicine(WM)CPGs were developed as EB guidelines.All TCM CPGs and most IM CPGs were identified as CB guidelines.Only the 2011 IBS and IM CPG was a CB-EB set of guidelines.Antispasmodics and peppermint oil for pain,loperamide for diarrhea,and linaclotide for constipation polyethylene glycol and lactulose as osmotic laxatives,bisacodyl and sodium picosulfate as stimulant laxatives,lubiprostone and linaclotide as prosecretory agents,and prucalopride were strongly recommended or recommended in FC.TCM interventions were suggested based on pattern differentiation,while the recommendation level was considered to be weak or insufficient.CONCLUSION WM CPGs generally provide a comprehensive management algorithm,although there are still some gaps that could be addressed with TCM.Specific high-quality trials are needed to enrich the evidence.

Effect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients

AIM： To evaluate the effect of sumatriptan, a selective 5-HT1 agonist, on anorectal function in irritable bowel syndrome （IBS） patients. METHODS： Twenty-two IBS patients selected according to the Rome II criteria （F 15, M 7; mean age 29.3±6.8, range 22-44 years） were examined. The study was blind, randomized and placebo-controlled with a crossover design. Anorectal manometry and rectal balloon distension test were performed before and after the administration of placebo and sumatriptan. RESULTS： The administration of sumatriptan caused a significant increase in the resting anal canal pressure from 9.2±2.0 kPa to 13.1±3.3 kPa （P〈0.0001） connected with the increase in the anal sphincter length and high pressure zone. After sumatriptan injection a remarkable increase in the threshold for the first sensation from 27±9 mL to 34±12 mL （P〈0.05） and urge sensation from 61±19 mL to 68±18 mL （P〈0.01） was observed. Sumatriptan did not affect either the volume evoking the rectoanal inhibitory reflex or the results of the straining test. CONCLUSION： 5-HT1 receptors participate in the regulation of anorectal function. Elucidation of the role of 5-HT1 receptors in the pathophysiological mechanisms of IBS may have some therapeutic implications.

Diagnosis and management of functional symptoms in inflammatory bowel disease in remission

Inflammatory bowel disease(IBD) patients in remission may suffer from gastrointestinal symptoms that resemble irritable bowel syndrome(IBS). Knowledge on this issue has increased considerably in the last decade, and it is our intention to review and summarize it in the present work. We describe a problematic that comprises physiopathological uncertainties, diagnostic difficulties, as IBS-like symptoms are very similar to those produced by an inflammatory flare, and the necessity of appropriate management of these patients, who, although in remission, have impaired quality of life. Ultimately, from almost a philosophical point of view, the presence of IBS-like symptoms in IBD patients in remission supposes a challenge to the traditional functional-organic dichotomy, suggesting the need for a change of paradigm.

Patients with functional bowel disorder have disaccharidase deficiency:A single-center study from Russia

BACKGROUND Functional bowel disorder(FBD)may be caused by a decrease in disaccharidase activity.Thus,the timely diagnosis of disaccharidase deficiency could lead to a better prognosis in patients with this condition.AIM To determine the potential value of intestinal disaccharidases glucoamylase,maltase,sucrase,and lactase in understanding the etiology and pathogenesis of FBD.METHODS A total of 82 FBD patients were examined.According to the Rome IV criteria(2016),23 patients had diarrhea-predominant irritable bowel syndrome(IBS),33 had functional diarrhea,10 had constipation-predominant IBS,4 had functional constipation,and 12 had mixed IBS.The Dahlqvist method was used to measure disaccharidase activity in the brush-border membrane of mature enterocytes of the small intestine,in duodenal biopsies obtained during esophagogastroduodenoscopy.RESULTS Lactase deficiency was detected in 86.5%of patients,maltase deficiency in 48.7%,sucrase deficiency in 50%,and glucoamylase deficiency in 84.1%.The activities of all enzymes were reduced in 31.7%of patients,and carbohydrase deficiency was detected in 63.5%of patients.The low activity of enzymes involved in membrane digestion in the small intestine was found in 95.2%of patients.CONCLUSION In 78 of the 82 patients with FBD,gastrointestinal symptoms were associated with disaccharidase deficiency.

Five-year follow-up of 263 cases of functional bowel disorder

AIM: To determine the mortality associated with functional bowel disorders (FBDs) and their possible relationship with organic bowel disease. METHODS: Patients who satisfied the Rome Ⅲ criteria for FBD (retrospective diagnosis) were followed up by telephone interview and/or outpatient review at 5 years after their first attendance. The patients were divided into the following groups: irritable bowel syndrome, functional abdominal bloating, functional constipation, functional diarrhea and unspecified FBD. The survival of the FBD patients overall and of those with each FBD were compared with data obtained from the Guangzhou population in 2005. The incidences of colonic cancer overall and for each FBD were compared with data from the Chinese population obtained from 56 cancer registries in 19 provinces of the country in 2008. RESULTS: Two hundred and sixty-three patients were followed-up. Five patients died, which was not significantly different from the expected survival rate. No differences in mortality among the FBDs were found. There were nine cases of organic bowel disease: three colonic cancers and six colonic polyps. The incidence of colonic cancer in FBD patients was higher than that in the general Chinese population (0.23% vs 0.03%, P < 0.05). There were significant differences in the incidence of colonic cancer among the FBDs (0/134, 0/24, 2/29, 1/66, 0/10, respectively, P<0.05); functional constipation was the most common. The incidence of colonic polyps was similar among the FBDs. The baseline age of patients who died was greater than that of those who survived (66.60±6.84 years vs 45.14±10.34 years, P<0.05). The baseline age of patients who had colonic cancer or polyps during follow-up was greater than that of those without colonic cancer or polyps (60.33±1.53 years vs 45.38±10.62 years; 54.50±6.47 years vs 45.34±10.68 years, P<0.05). CONCLUSION: FBDs do not increase the risk of death. The incidence of colonic cancer in patients with FBDs may be increased, especially in those with functional constipation and in the elderly.

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends

Inflammatory bowel disease(IBD) is a serious health concern among western societies. The disease is also on the rise in some East Asian countries and in Australia. Health professionals and dietitians around the world are facing an unprecedented challenge to prevent and control the increasing prevalence of IBD. The current therapeutic strategy that includes drugs and biological treatments is inefficient and are associated with adverse health consequences. In this context, the use of natural products is gaining worldwide attention. In vivo studies and clinical evidence suggest that wellplanned dietary regimens with specific nutrients can alleviate gastrointestinal inflammation by modulating inflammatory cytokines, such as tumor necrosis factor α(TNF-α), interleukin 1(IL-1), IL-6, IL-1β, and IL-10. Alternatively, the avoidance of high-fat and highcarbohydrate diets is regarded as an effective tool to eliminate the causes of IBD. Many functional foods and bioactive components have received attention for showing strong therapeutic effects against IBD. Both animal and human studies suggest that bioactive functional foods can ameliorate IBD by downregulating the pro-inflammatory signaling pathways, such as nuclear factor κB, STAT1, STAT6, and pro-inflammatory cytokines, including IL-1β, IL-4, IL-6, COX-2, TNF-α, and interferon γ. Therefore, functional foods and diets have the potential to alleviate IBD by modulating the underlying pathogenic mechanisms. Future comprehensive studies are needed to corroborate the potential roles of functional foods and diets in the prevention and control of IBD.

A New Immunofluorescence Assay for Fecal Calprotectin Distinguishes Inflammatory Bowel Disease from Functional Bowel Disease

Aims: To investigate the diagnostic value of fecal calprotectin (FC) determined by a new immunofluorescence assay-fluorescence enzyme immunoassay (FEIA) in patient with inflammatory bowel disease (IBD) or functional bowel disease, compared with the typical ELISA kit. Methods: FC was determined simultaneously by FEIA and an ELISA kit in 26 patients with functional bowel disease and 77 patients with IBD. We compared the difference of FC levels between patients with IBD and patients with functional bowel disease. Receiver operating characteristics curve (ROC) was constructed to obtain the optimal cut-off value of FC for distinguishing IBD from functional bowel disease and the corresponding sensitivity and specificity. Results: The median FC levels of patients with IBD in clinical active stage or clinical remission stage was significantly higher than that of patients with functional bowel disease. The median FC levels of patients with IBD in clinical active stage, IBD in clinical remission stage and functional bowel disease were as follow: 699.91 (346.14 ~ 1647.54) μg/g;407.36 (121.81 ~ 878.48) μg/g;39.04 (12.09 ~ 81.04) μg/g when FC was measured by FEIA. The median FC levels were 716.99 (240.42 ~ 1232.53) μg/g;338.46 (53.08 ~ 692.82) μg/g;41.44 (11.77 ~ 73.19) μg/g among such above three groups of patients respectively, when FC was measured by ELISA kit. The diagnostic value of IBD with FC determined by FEIA (optimal cut-off = 131.79 μg/g) and ELISA kit (optimal cut-off = 121.85 μg/g) presented an area under the curve of 0.881 and 0.873, respectively. Conclusions: FC determined by FEIA was an accurate surrogate marker to distinguish IBD from functional bowel disease.

The Correlation between Sexuality and Family Functioning among Patients with Inflammatory Bowel Disease in Japan

Purpose: The objective of this study was to examine the correlation between the sexuality of patients with Inflammatory Bowel Disease and family functioning. Methods: The study took the form of a self-administered questionnaire survey, utilizing the Sexuality Satisfaction Index for IBD (SEXSI-IBD) for measuring sexuality and the Survey of Family Environment Survey of Family Environment (SFE) for measuring family functioning. SEXSI-IBD consists of 28 items and five domains, and SFE consists of 30 items and five domains. The participants were recruited at 15 self-help groups and 14 hospitals. Results: Of 146 participants, 48.6% were male and 52.4% female, with an average age of 41.1 years. A significant correlation was observed between the item average score of SEXSI-IBD and Overall Satisfaction Score (OSS) of SFE. Significant correlations were observed in two domains of the SEXSI-IBD, “Daily interaction” and “Sexual communication,” and in all five domains of the SFE. In particular, for “Daily interaction,” the strongest correlation was observed in the SFE’s “Macro system” and “Family internal environment system.” A correlation was observed between the “Physical contact importance” in SEXSI-IBD and the “Macro system” in the OSS of the SFE. Conclusions: Sexuality correlates with family functioning not only in the family internal environment system but also in the family external environment system. Through an approach aimed at elevating the degree of satisfaction for sexuality, it becomes possible to improve family functioning and realize a sense of family well-being.

Management of Overlap Syndrome between Functional Dyspepsia and Irritable Bowel Syndrome by Western and Traditional Chinese Medicine

The overlap syndrome of functional dyspepsia and irritable bowel syndrome (FD-IBS) is very common and difficult to treat. There are many risk factors of FD-IBS. Mental illness of FD-IBS patients is more serious. Functional dyspepsia and irritable bowel syndrome have some similarities in the aspects of pathophysiology, pathogenesis, and treatment. We should pay attention to two aspects of the treatment of overlap syndrome, one is simplifying medications, the other is using gastrointestinal motility drug with bidirectional regulative function when necessary. Traditional Chinese medicine in this respect shows some advantages. This review addresses the epidemiology, risk factors, clinical features, pathogenesis and management of FD-IBS.

阴道封闭术对老年盆腔器官脱垂患者肠道功能的影响及相关因素

目的探讨阴道封闭术对老年盆腔器官脱垂患者肠道功能的影响,分析术后肠道功能改善的相关因素。方法收集2020年6月至2022年6月因盆腔器官脱垂行阴道封闭术患者104例的临床及盆底超声资料,应用盆底功能障碍问卷(PFDI-20)于术前、术后12个月进行肠道症状及生活质量调查,分析肠道症状。结果104例患者中,56.7%(59/104)的患者术前至少存在一项肠道症状,术后38.5%(40/104)的患者至少存在一项肠道症状;其中梗阻性排便功能障碍术后为37.5%(39/104)较术前50.5%(52/104)明显缓解,差异有统计学意义(P<0.05),而失禁性肠道症状和刺激性肠道症状术后发生率较术前虽有下降,但差异无统计学意义(P>0.05)。术前59例有肠道症状者术后62.7%(37/59)得以改善,33.9%(20/59)的患者症状持续存在,3.4%(2/59)的患者出现症状加重。45例术前无任何肠道症状患者中术后出现任一肠道症状7例,术后新发肠道症状发生率为15.6%。术后对阴道封闭术后悔者2例,后悔率1.9%(2/104)。应用PFDI-20中的手助排便和结直肠肛门困扰量表(CRADI-8)评分,梗阻性症状中位评分术前16.67分(16.67,41.67),术后8.33分(0,16.67),术后评分较术前显著下降(P<0.05);而失禁性症状和疼痛/刺激性症状术前与术后比较差异无统计学意义(P>0.05)。多因素分析显示,存在直肠膨出者行阴道封闭术后肠道症状缓解率较高;阴道封闭术同时行会阴体修补是肠道症状缓解的保护因素(OR 0.151,95%CI:0.035~0.645)。结论阴道封闭术可有效改善老年盆腔器官脱垂患者的梗阻性排便症状,新发肠道症状较少见,合并直肠膨出的POP患者行阴道封闭术同时行会阴体修补术有助于缓解肠道症状。

电针“天枢”与“天枢”配伍“上巨虚”对肠易激综合征大鼠行为学和结肠功能的影响

目的观察并比较电针“天枢”与“天枢”配伍“上巨虚”对肠易激综合征(irritable bowel syndrome,IBS)模型大鼠情绪和结肠功能影响,初步探讨天枢配伍上巨虚是否存在协同或叠加效应。方法雄性Wistar大鼠分为空白组(10只)和造模组(45只),采用慢性和急性应激相结合方法连续干预10 d制备模型,将制备成功IBS模型大鼠随机分为模型组(8只)、天枢组(8只)、天枢配伍上巨虚组(8只);天枢组、天枢配伍上巨虚组连续电针干预治疗14 d;干预结束后,分别对各组大鼠进行高架十字迷宫实验、结肠痛敏阈值测定,检测血清5-羟色胺(5-hydroxytryptamine,5-HT)含量以及结肠5-羟色胺4受体(5-hydroxytryptamine 4 receptor,5-HT 4 R)蛋白表达。结果与模型组比较,电针天枢组、电针天枢配伍上巨虚组进入开放臂(open arm entry,OE)次数百分比和开臂停留时间(open arm time,OT)百分比增加(P<0.01);结肠痛敏阈值显著升高(P<0.01);血清5-HT含量减少(P<0.05);结肠5-HT 4 R蛋白相对表达量增加(P<0.05)。两电针组之间比较,OE%、OT%、结肠痛敏阈值、血清5-HT含量以及结肠5-HT 4 R蛋白相对表达量的差异无统计学意义。结论电针“天枢”与“天枢”配伍“上巨虚”均能调节大鼠情绪心理行为的异常和改善结肠功能紊乱症状,但电针“天枢”配伍“上巨虚”相较于电针“天枢”未表现明显的穴位协同或叠加效应。

慢性避水应激法建立大鼠肠易激综合征模型及其评价

目的:探讨慢性避水应激(WAS)法建立肠易激综合征(IBS)大鼠模型的方法,并评价其可行性。方法:30只雄性清洁型Wistar大鼠,随机分为对照组(n=10)和模型组(n=20),模型组大鼠每日采用WAS法诱导1 h,连续干预造模10 d;对照组大鼠不进行任何干预。造模结束后,观察并记录2组大鼠一般情况和体质量,采用高架十字迷宫(EPM)实验检测2组大鼠进入开放臂次数(OE)百分率和进入开放臂时间(OT)百分率,腹壁撤回反射(AWR)实验检测2组大鼠内脏敏感性,心电图检查2组大鼠心率变异性(HRV),腹外斜肌肌电图(EMG)检测2组大鼠结直肠痛敏阈值,多通道生理信号记录仪检测2组大鼠结肠慢波频率。结果:2组大鼠在整个造模期间均无死亡情况,造模结束后,模型组大鼠均伴有精神状态欠佳、自主活动减少、少动、皮毛散乱且无光泽、易激惹和肛门口不净等情况;对照组大鼠精神状态、自主活动、皮毛和肛周无明显变化。与对照组比较,模型组大鼠体质量明显降低(P<0.05)。EPM实验,与对照组比较,模型组大鼠OE百分率和OT百分率均明显降低(P<0.01)。AWR实验,模型组中AWR半定量评分≥3分大鼠共12只,内脏痛大鼠模型造模成功率为60%。与对照组比较,模型组大鼠低频信号(LF)和LF/高频信号(HF)比值均明显升高(P<0.01),HF明显降低(P<0.05)。EMG法,与对照组比较,模型组大鼠结肠痛敏阈值明显降低(P<0.01),结肠慢波频率明显升高(P<0.01)。结论:采用WAS法建立IBS大鼠模型,大鼠行为及精神情绪改变、内脏敏感性升高、结肠慢波频率加快和自主神经系统平衡性紊乱,WAS法可作为一种有效的造模方式,用于观察和评价IBS治疗的相关药物及干预方法。

六磨汤联合芒硝外敷对术后早期炎性肠梗阻患者肠道屏障功能及血清血管活性肠肽水平的影响

目的:探讨六磨汤联合芒硝外敷对术后早期炎性肠梗阻(EPISBO)患者肠道屏障功能及血清血管活性肠肽(VIP)水平的影响。方法:选取2021年11月—2022年11月我院收治的符合标准的98例EPISBO患者,采用随机数字表法分为对照组(n=49)及研究组(n=49)。对照组进行常规治疗,研究组在对照组的基础上给予六磨汤联合芒硝外敷治疗。比较两组临床疗效、治疗前后胃肠功能恢复时间、胃肠激素水平、血清炎症因子水平和不良反应发生率。结果:研究组总有效率高于对照组(91.84%vs 75.51%,P<0.05)。研究组腹部症状缓解时间、肠鸣音恢复时间以及肛门排气时间均低于对照组(6.37±0.97 vs 8.56±1.29,5.31±0.76 vs 7.16±0.93,6.37±1.09 vs 8.16±1.16,P<0.05)。治疗前,两组的血清VIP、胃动素(MOT)、胃泌素(GAS)水平无统计学差异(31.76±5.87 vs 31.08±5.63,187.29±26.39 vs 186.32±25.97,108.67±21.76 vs 111.62±26.89,P>0.05),治疗后,两组的血清VIP水平都有所降低,MOT、GAS水平都有所升高,相对而言,研究组的血清VIP水平降低更多,MOT、GAS水平升高更多(16.23±3.66 vs 20.75±4.37,289.67±38.52 vs 231.56±31.26,179.65±39.55 vs 142.34±31.76,P<0.05)。治疗前,两组的血清肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-6(IL-6)水平无差异(65.19±7.83 vs 63.13±7.56,67.59±9.27 vs 67.11±8.96,59.13±8.52 vs 58.77±8.78,P>0.05),治疗后,两组的血清TNF-α、CRP、IL-6水平都有所降低,且研究组的血清TNF-α、CRP、IL-6水平降低更多(19.37±3.65 vs 29.82±5.23,17.26±3.25 vs 27.51±4.16,15.56±2.44 vs 23.41±3.53,P<0.05)。结论:六磨汤联合芒硝外敷可有效改善EPISBO患者的临床症状,降低胃肠功能恢复的时间,调节胃肠激素水平和血清炎症因子,且具有一定的安全性。

探讨针刺治疗肠易激综合征的多穴配伍特点研究

通过回顾针灸治疗肠易激综合征(IBS)的常用腧穴特性及共性,并尝试归纳腧穴配伍规律。即基于腧穴的主治原则,选取疾病相关特异性腧穴,结合主治相同或相似的共效穴,在针灸双向调节机能的效应下,充分发挥“多穴共效,协同增效”的目的,为临床肠易激综合征腧穴配伍提供依据。

先天性巨结肠Soave术后远期排便功能不良的危险因素分析

目的探讨先天性巨结肠(Hirschsprung's disease,HD)患儿接受Soave术后的远期排便功能情况,为HD的临床诊疗提供依据。方法本研究为回顾性研究,收集2011年1月至2020年12月首都医科大学附属北京儿童医院普外科收治的280例HD患儿临床资料,并进行电话随访,随访时间7.2(5.4,9.7)年;随访内容依据Rintala量表确定,包括排便控制能力、排便感觉、排便频率、污粪、便秘等。根据Rintala评分结果,将HD患者分为排便功能不良组(Rintala评分<12分)和排便功能一般或良好组(Rintala评分≥12分),分析远期排便功能不良的危险因素。结果280例HD患儿Rintala评分为18(15,20)分,其中189例(189/280,67.5%)排便功能评分等级为良好(Rintala评分≥17分),65例(65/280,23.2%)排便功能评分等级为一般(Rintala评分12~16分),26例(26/280,9.3%)排便能评分等级为较差(Rintala评分<12分);90.0%(252/280)的患儿有相对正常的感知大便的能力;污粪频率大于1次/周者占35.0%(98/280);仅5.7%(16/280)的患儿出现便秘,术后需要泻药(如开塞露)辅助排便;4.3%(12/280)的患儿存在社交活动受限/障碍。单因素分析发现,巨结肠类型为短段型和再手术是Soave术后远期排便功能不良的危险因素(P<0.05)。结论污粪是Soave术后远期排便功能损害的主要表现;短段型巨结肠和再手术与Soave术后远期排便功能有关。